Daptomycin is a cyclic lipopeptide antibiotic. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Daptomycin has an FDA-approved product on the U.S. market, marketed as Daptomycin under application ANDA216445.
The current label is held by NorthStar RxLLC.
From the FDA label
aptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). Limitations of Use: • Daptomycin for injection is not indicated for the treatment of pneumonia. • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus.Quoted from the FDA-approved prescribing information
The evidence
One source on Daptomycin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Daptomycin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides